Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405879 | 0.82 | CTSK (0.53) | CTSKCTSSCTSLKCNH2SMN1; SMN2 | |
| SCHEMBL3402065 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2MAPT | |
| SCHEMBL3400747 | 0.79 | CTSK (0.43) | CTSKCTSSCTSLKCNH2SMN1; SMN2 | |
| SCHEMBL3401805 | 0.77 | CTSK (0.67) | CTSKCTSSCTSLKCNH2SMN1; SMN2 | |
| SCHEMBL3425396 | 0.77 | ALDH1A1 (0.45) | CTSKCTSSCTSLKCNH2SMN1; SMN2 | |
| SCHEMBL3406926 | 0.77 | CTSK (0.53) | CTSKCTSSCTSLKCNH2SMN1; SMN2 | |
| SCHEMBL3400756 | 0.74 | SMN1; SMN2 (0.43) | CTSKCTSSCTSLKCNH2SMN1; SMN2 | |
| SCHEMBL2641385 | 0.74 | CTSK (0.60) | CTSKCTSSCTSLKCNH2SMN1; SMN2 | |
| SCHEMBL3427397 | 0.73 | CTSK (0.42) | CTSKCTSSCTSLKCNH2SMN1; SMN2 | |
| SCHEMBL4969772 | 0.70 | JAK2 (0.48) | CTSKCTSSCTSLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | CTSK 2218/4885CTSS 4111/4885CTSL 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.